GlassScriptPhysician profile
Jared L Thomas
NPI 1487995528
$1,943.31
in general payments reported to CMS, 2019-2025
23 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $862 · 2023: $301 · 2024: $146 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $475.04 | 2021-2025 | General - Pain Management, Intracept |
| Abbvie INC. | $401.80 | 2021-2023 | |
| Nevro Corp. | $227.17 | 2022-2024 | Senza |
| Collegium Pharmaceutical, INC. | $185.82 | 2021-2022 | |
| Novo Nordisk INC | $110.05 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $65.16 | 2021 | |
| Pfizer INC. | $64.48 | 2023-2024 | |
| Axonics, INC. | $54.18 | 2023 | Axonics |
| Medtronic, INC. | $51.49 | 2022-2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $39.39 | 2022-2023 | Reyvow, Emgality |
| Globus Medical, INC. | $25.33 | 2025 | Senza |
| Impel Pharmaceuticals INC. | $24.59 | 2023 | Trudhesa |
| Virtus Pharmaceuticals LLC | $24.47 | 2024 | Levorphanol Tartrate |
| Abbott Laboratories | $24.29 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.99 | 2025 | Relistor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.83 | 2022 | |
| Averitas Pharma INC. | $20.08 | 2023 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $19.02 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.80 | 2022 | |
| Orexo US, INC. | $17.16 | 2023 | Zubsolv |
| Glaxosmithkline, LLC. | $15.31 | 2025 | Trelegy Ellipta |
| Baxter Healthcare | $14.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.